絞り込み

16532

広告

Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an mutation.

著者 Barrón F , Cardona AF , Corrales L , Ramirez-Tirado LA , Caballe-Perez E , Sanchez G , Flores-Estrada D , Zatarain-Barrón ZL , Arrieta O ,
J Thorac Dis.2018 Apr ; 10(4):2166-2178.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (30view , 0users)

Full Text Sources

Miscellaneous

Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to progression such as clinical patterns of progression (dramatic, gradual, and local) with the prognosis of NSCLC patients treated with tyrosine kinase inhibitors (TKIs).
PMID: 29850120 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード